Recently, the field of cancer treatment in China has achieved a significant milestone. On January 7, 2025, the National Medical Products Administration officially approved the innovative drug SHR-1701 for market use. It is indicated in combination with chemotherapy as a first-line treatment for locally advanced unresectable, recurrent, or metastatic gastric and gastroesophageal junction adenocarcinoma with PD-L1 positivity (CPS≥1). This approval offers a new and promising treatment option for patients worldwide with advanced gastric cancer.
**Innovative Therapy Significantly Extends Survival**
This approval is based on the pivotal Phase III RELIGHT study. Data presented at the 2024 European Society for Medical Oncology Annual Meeting demonstrated the significant efficacy of the SHR-1701 plus chemotherapy regimen: in the intention-to-treat population, the median overall survival reached 15.8 months, with a 34% reduction in the risk of death. For patients with advanced gastric cancer, who typically have a poor prognosis, this represents a substantial and significant improvement in survival.
**A Direct Bridge to Cutting-Edge International Treatment**
For gastric cancer patients worldwide seeking the most effective treatment options, the approval of this new drug presents an important opportunity. The Beijing South Region Oncology Hospital International Department, serving as a professional platform connecting international patients with top-tier oncology treatment resources in China, can now provide eligible international patients with advanced, personalized comprehensive treatment plans, including the SHR-1701 combination therapy.
We are deeply aware of the challenges faced by international patients seeking medical care. Therefore, we offer comprehensive support services, including:
* **Professional Medical Consultation and Medical Record Evaluation:** Senior oncology expert teams review medical records and provide feasibility analysis for treatment.
* **Personalized Treatment Planning:** Development of comprehensive treatment strategies incorporating new drugs, based on international guidelines and the latest clinical practices in China.
* **Full-Cycle Coordination Services:** Assistance with medical visa processing, appointment scheduling, hospitalization arrangements, language interpretation, and logistical support.
**Contact Us Now to Open Your Exclusive Health Pathway**
If you or your family are facing the challenge of gastric cancer and wish to learn more about the new SHR-1701 therapy or other advanced treatment options, please contact the Beijing South Region Oncology Hospital International Department immediately through any of the following methods. Our professional team is ready to assist you.
**Preferred Contact Methods:**
- **Phone:** 400-880-3716
- **WeChat:** 17801183037 (Please add the note “International Patient Inquiry”)
**Email:**
- 100085_010@163.com
- myimmnet@163.com
Please send relevant medical record summaries, pathology reports, and imaging materials to the above email addresses. We will arrange for expert pre-evaluation as soon as possible.
The Beijing South Region Oncology Hospital International Department is committed to providing high-quality, evidence-based, patient-centered medical care to patients from around the world, adhering to international standards of medical service. We look forward to helping you connect with hope and walk this journey alongside you.
Post time: Jan-27-2026